INMT Appears Near the Golgi in Human Neurons, Pointing to a Cellular Site for Endogenous DMT
Human neurons may house a previously unrecognized biochemical compartment for psychedelic tryptamine production. In a new preprint, investigators validated an anti-INMT antibody and used immunocytochemistry in human induced pluripotent stem cell-derived neurons to place indolethylamine N-methyltransferase close to the cytosolic face of the cis-Golgi network, where it sat near other enzymes involved in DMT biosynthesis.
The work adds protein-level localization data to a question that has lingered since Julius Axelrod’s early studies showed DMT production in human tissues. DMT has been proposed as an endogenous neuromodulator because it acts as a serotonin 2A receptor agonist, but the enzyme responsible for its formation had not been characterized at the protein level in the human central nervous system. This study narrows that gap by moving from biochemical inference to cellular anatomy.
The Golgi finding is the central result. INMT immunoreactivity appeared in close proximity to the cis-Golgi network, and the signal was observed across multiple neuronal Golgi phenotypes. In the same cellular system, both DMT-like and 5-HT2A receptor immunoreactivity also partially localized near the Golgi apparatus. In practical terms, the data suggest that the machinery for making a psychedelic tryptamine and a receptor capable of detecting it may occupy neighboring intracellular territory rather than remaining confined to the extracellular surface of the neuron.
That proximity matters because the Golgi is not a passive sorting station. Its membranes and surrounding cytosolic face create a localized environment in which enzyme clustering can concentrate substrates, channel intermediates, and shape where signaling molecules accumulate. If INMT is active in this region, it could generate a microdomain enriched in membrane-permeable psychedelic tryptamines. Those molecules would not need to wait for synaptic release to exert effects; they may be able to diffuse intracellularly and encounter receptor pools already positioned near the same organelle.
A Candidate Microdomain for Psychedelic Tryptamine Biosynthesis
The authors propose the cis-Golgi network as a candidate microdomain for psychedelic tryptamine biosynthesis, and the argument rests on localization rather than on functional readouts. The study does not establish enzyme kinetics, substrate flux, or in-cell production rates. It does, however, define a plausible anatomical setting for the enzymatic steps that would be needed to generate endogenous DMT.
This is a significant shift in how the field can think about endogenous psychedelics. Rather than imagining a diffuse cytoplasmic pool, the data point toward a structured intracellular neighborhood where biosynthetic enzymes sit near the site of receptor access. For a lipophilic or membrane-permeable compound such as DMT, compartmentalization could determine whether the signal remains local, spreads through the cytosol, or reaches a receptor population embedded in the same subcellular domain.
One sentence captures the practical consequence: the neuron may be organizing psychedelic chemistry around the Golgi itself.
The study also broadens the relevance of the Golgi beyond classical trafficking biology. A receptor localized in proximity to the Golgi raises the possibility of intracellular signaling pathways that do not depend solely on canonical plasma membrane events. The authors’ model places biosynthesis and receptor engagement in a shared compartmental framework, which is mechanistically attractive even as it remains provisional until tested with functional experiments.
Why the Validation Step Matters for Human Neurobiology
Before localization studies can inform mechanism, the antibody has to be credible. The investigators report that they validated an anti-INMT antibody before using it in human induced pluripotent stem cell-derived neurons. That step is essential because protein localization claims are only as strong as the specificity of the reagent used to detect the target.
By anchoring the analysis in human neurons rather than a heterologous expression system, the study also keeps the biology close to the tissue of interest. The central nervous system has its own trafficking logic, organelle organization, and receptor distribution patterns. A localization map derived from human neurons therefore carries more direct relevance for endogenous tryptamine biology than a purely nonhuman or non-neuronal model would.
Still, the findings remain anatomically descriptive. The preprint establishes the first protein-level characterization of INMT in human neurons, but it does not show that neuronal INMT is sufficient to produce measurable DMT in this system, nor does it show that Golgi-adjacent receptor pools are required for any particular signaling response. Those are the next questions, and they will need biochemical, imaging, and functional assays that can connect location to output.
Implications for Psychedelic Mechanism Research
Interest in psychedelics has accelerated because of their emerging clinical efficacy in neuropsychiatric disorders, but mechanism remains a major limitation in translating therapeutic enthusiasm into durable biology. This work offers a concrete cellular framework for asking where endogenous psychedelic signaling might originate. If the cis-Golgi serves as a production site for tryptamine signaling molecules, then future studies can focus on how that microdomain is regulated, which substrates feed it, and whether neuronal state changes alter its activity.
The authors also suggest that these findings may help efforts to understand the mechanism of action of psychedelics under clinical investigation and to target endogenous tryptamines therapeutically. That remains a broad translational claim, but the cellular map is specific. It identifies where to look next rather than presuming that endogenous psychedelics act in a nonspecific cytosolic haze.
This is also the sort of preclinical result that can redirect experimental design. Imaging, proximity assays, and perturbation studies can now be aimed at a defined organelle-associated compartment instead of an undifferentiated neuron. If the field can show that this Golgi-associated localization translates into measurable chemistry and signaling, the idea of endogenous psychedelic neuromodulation will move from a provocative hypothesis to a tractable cellular pathway.
For now, the preprint stops at localization. Its strongest claim is also its cleanest one: INMT sits near the cis-Golgi in human neurons, and that neighborhood may be where endogenous psychedelic tryptamine biology begins.